CalciMedica raises up to $55M in private placement; $20.4M upfront from new and existing investors

CalciMedica, Inc.

Upfront gross proceeds $20.4M from sale of 5.1M shares and pre-funded warrants to purchase 351,352 shares at $3.70/share.
Additional up to ~$34.2M possible if Tranche A ($5.36/share) and Tranche B ($7.15/share) warrants are exercised in cash.
Tranche A warrants expire earlier of 30 days after topline AP data or Dec 31, 2024; Tranche B earlier of 30 days after AKI data or Dec 31, 2026.
Cash, equivalents and short-term investments were $11.2M as of Dec 31, 2023 (preliminary); proceeds expected to fund Phase 2 trials in AP and AKI.
New investors include Deerfield Management, Soleus Capital, Stonepine Capital, Aisling Capital; JonesTrading as placement agent.

item 1.01 item 2.02 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CalciMedica, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at upfront gross proceeds from the Private Placement of $20.4 million (effective 2024-01-19).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: upfront gross proceeds from the Private Placement of $20.4 million
Effective: 2024-01-19

Exact text from the filing

On January 19, 2024, CalciMedica, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”)

View on SEC.gov

623 material agreements filed in the last 30 days. Browse all material agreements →

CalciMedica, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-011738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.